MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
An Interview With Peter Schneider, MD
Dr. Schneider discusses treating CLI patients, additions to the 2009 VIVA meeting, and what we can expect to see from the vascular field in the next few years.
By Peter Schneider, MD
Perspectives on Access and Closure
A multispecialty panel's insights into current challenges and recent developments.
With Gary Ansel, MD; Frank Arko, MD; J.A. Mustapha, MD; Peter Schneider, MD; and Jos C. van den Berg, MD, PhD
Sponsored by FastWave Medical
The Next Wave of Intravascular Lithotripsy: A Panel Interview on Advances in Treating Calcific PAD
With Arthur Lee, MD; Amir Kaki, MD; Miguel Montero-Baker, MD; Venkatesh Ramaiah, MD, FACS; and Peter Schneider, MD
Updated TCAR Data Presented From Silk Road Medical's ROADSTER 1 and 2 Studies
November 29, 2017—Silk Road Medical, Inc. announced data from the ROADSTER 1 and 2 trials demonstrating the safety and efficacy of the company’s Enroute transcarotid neuroprotection and Enroute transcarotid stent system, which are specifically designed and indicated for transcarotid artery revascularization (TCAR).
Endologix TORUS 2 Study Completes Enrollment
November 23, 2021—Endologix LLC announced the completion of enrollment in the TORUS 2 IDE clinical study.
Healthcare Inroads Announces Global Launch
March 14, 2024—Healthcare Inroads, LLC, (HCIR) announced its launch as a partnership of clinicians and allied specialists dedicated to accelerating the goals and milestones of medical device companies, investors, and health care systems in the United States, Europe, and Asia.
Enrollment Begins in SCAFFOLD Study for Gore Carotid Stent
September 12, 2013—Gore & Associates (Flagstaff, AZ) announced commencement of enrollment in SCAFFOLD, the Gore Carotid Stent Clinical Study for the Treatment of Carotid Artery Stenosis in Patients at Increased Risk for Adverse Events from Carotid Endarterectomy.
Cagent Vascular's Serranator Alto Balloon Catheter Receives FDA Clearance
February 27, 2017—Cagent Vascular announced US Food and Drug Administration 510(k) clearance of the company's first product, the Serranator Alto percutaneous transluminal angioplasty serration balloon catheter for the treatment of peripheral artery disease.
Diabetes Subgroup Analysis from Medtronic's IN.PACT SFA Trial Presented
November 4, 2014––Medtronic, Inc. announced that the company’s In.Pact Admiral drug-coated balloon (DCB) demonstrated consistently favorable results in patients with diabetes being treated for peripheral artery disease in above-the-knee leg arteries in the company’s landmark IN.PACT SFA trial study.
Intact Vascular's Tack-it Endovascular Stapler Receives CE Mark Approval
April 10, 2012—Intact Vascular (Wayne, PA) announced that it has received CE Mark approval for its Tack-it endovascular stapler.
Angiolutions Appoints International Endovascular Experts to Its Medical Board
April 29, 2026—Angiolutions announced the appointment of four internationally recognized vascular and endovascular specialists to its Medical Board, which will support the company as it advances development of the investigational A3-Shield system.
New Paclitaxel Meta-Analysis Questions Safety in CLI Population; Concerns Voiced as to Methods
January 15, 2020—In the wake of a year spent scrutinizing the finding of a mortality signal related to paclitaxel-coated balloons and stents in the superficial femoral artery (SFA), a new publication again calls the safety of paclitaxel into question, only this time in the critical limb ischemia (CLI) population.
Provisio Medical Names Physician Advisory Board to Help Guide Commercialization
May 6, 2024—Provisio Medical, Inc. announced the formation of a Physician Advisory Board composed of a multidisciplinary group of physicians who will provide input and feedback on product development decisions, outcome-focused clinical studies, and therapeutic applications of Provisio’s core sonic lumen tomography intravascular ultrasound (SLT IVUS) technology for the treatment of patients with peripheral artery disease.
Studies Presented for Profusa's Lumee Oxygen Platform in PAD Patients
January 29, 2019—Profusa announced that clinical data from two studies evaluating the company's Lumee oxygen platform were presented at LINC, the Leipzig Interventional Course held January 22–25 in Leipzig, Germany.
An Interview With Andrew Holden, MBChB, FRANZCR, EBIR
Dr. Holden reflects on the legacy of paclitaxel and lessons learned from the controversy, research priorities for 2022, his philosophy for choosing which projects to accept, and more.
Medtronic's IN.PACT SFA II Drug-Eluting Balloon Study Completes Enrollment
January 23, 2013–Medtronic, Inc. (Minneapolis, MN) announced completion of enrollment in IN.PACT SFA II, the United States arm of its clinical study for the In.Pact Admiral drug-eluting balloon as a treatment for peripheral artery disease in the superficial femoral (SFA) and proximal popliteal arteries.
Provisio SLT IVUS System Launched
May 21, 2024—Provisio Medical, Inc., developer of sonic lumen tomography (SLT) technology to provide real-time blood vessel measurements during vascular interventions, recently announced the completion of the first commercial clinical cases utilizing the Provisio SLT intravascular ultrasound (IVUS) system.
Sponsored by Medtronic
Roundtable Discussion: Paclitaxel Safety and What We Have Learned
With William A. Gray, MD; Sahil A. Parikh, MD; and Peter A. Schneider, MD
Medtronic Completes Enrollment in IN.PACT SFA I DEB Study
May 16, 2011—At the EuroPCR 2011 conference in Paris, Medtronic, Inc. (Minneapolis, MN) announced recent developments from its clinical program for the In.Pact drug-eluting balloon (DEB) technology.
CMS Approves Coverage for PQ Bypass TORUS 2 IDE Trial
December 19, 2019—PQ Bypass Inc. announced it has received approval for coverage from the Centers for Medicare and Medicaid Services (CMS) for the TORUS 2 investigational device exemption (IDE) study.
